GSK PLC-SPON ADR (GSK) Stock Institutional Trading Activity


GSK PLC-SPON ADR (GSK) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q4 2025), investors with some of the largest reported share count changes include Causeway Capital Management, Renaissance Technologies LLC, Kahn Brothers Group, Hancock Classic Value, and Dodge & Cox Stock Fund. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.

Explore more:

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q4 2025Hancock Classic ValueBuy4,72713,444$659,292
Q4 2025Causeway Capital ManagementSell-1,143,10433,897$1,662,321
Q4 2025Renaissance Technologies LLCSell-952,3811,035,572$50,784,451
Q4 2025Kahn Brothers GroupSell-82,141178,696$8,763,251
Q3 2025Hancock Classic ValueBuy1,2078,717$376,237
Q3 2025Sequoia Financial AdvisorsBuy5,92932,674$1,410,214
Q3 2025Hillman Value FundSell-10,820141,779$6,119,182
Q3 2025Causeway Capital ManagementBuy69,9251,177,001$50,799,344
Q3 2025Renaissance Technologies LLCSell-262,9001,987,953$85,800,051
Q3 2025Dodge & Cox Stock FundSell-354,13578,403,734$3,383,905,159
Q3 2025Tweedy, Browne Co All Funds (US)Sell-4,62882,243$3,549,608
Q3 2025Kahn Brothers GroupSell-399,035260,837$11,257,724
Q2 2025Hancock Classic ValueBuy7,5107,510$288,384
Q2 2025Sequoia Financial AdvisorsBuy3,45126,745$1,027,028
Q2 2025Hillman Value FundSell-12,544152,599$5,859,802
Q2 2025Causeway Capital ManagementSell-8471,107,076$42,511,705
Q2 2025Renaissance Technologies LLCBuy268,7002,250,853$86,432,755
Q2 2025Dodge & Cox Stock FundBuy106,03678,757,869$3,024,302,170
Q2 2025Tweedy, Browne Co All Funds (US)Sell-3,67486,871$3,335,846
Q2 2025Kahn Brothers GroupBuy659,872659,872$25,339,084
Q1 2025Sequoia Financial AdvisorsBuy2,64923,294$902,411
Q1 2025Hillman Value FundSell-66,008165,143$6,397,640
Q1 2025Causeway Capital ManagementBuy31,3431,107,923$42,920,943
Q1 2025Renaissance Technologies LLCSell-773,0401,982,153$76,788,607
Q1 2025Dodge & Cox Stock FundBuy10,210,92178,651,833$3,046,972,010
Q1 2025Tweedy, Browne Co All Funds (US)Sell-3,27190,545$3,507,713
Q4 2024Sequoia Financial AdvisorsSell-2,29220,645$698,198
Q4 2024Hillman Value FundBuy34,255231,151$7,817,527
Q4 2024Causeway Capital ManagementBuy179,1741,076,580$36,409,929
Q4 2024Renaissance Technologies LLCBuy419,7002,755,193$93,180,627

Frequently asked questions about GSK activity

  • Which institutional owners are buying GSK?

    Institutional owners buying GSK include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in GSK activity?

    "Buy" means an investor increased their reported position in GSK compared to the prior reporting period. This reflects growing exposure to GSK PLC-SPON ADR (GSK) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in GSK increasing?

    Institutional interest in GSK can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.